DNA sequencing costs dropped below $600 in 2025. The global genetic testing market heads toward $91.3 billion by 2034.
Yet funding remains selective. Investors seek companies with proprietary sequencing technology, unique datasets, or novel applications. Consumer genetics faces scrutiny. Clinical applications attract capital.
This guide lists 30+ active genomics investors. Their focus areas range from DNA sequencing infrastructure to genetic testing platforms to CRISPR therapeutics.
We've compiled investment ranges, portfolio companies, and direct contacts.
Track your genomics pitch deck
Sequencing platform built. Clinical validation complete. Regulatory pathway clear.
Still, VCs aren't responding.
PDFs disappear into inboxes. You can't track engagement. Partners miss key data.
Use trackable links. See who reads your deck. Monitor time on technical slides.
Ellty simplifies pitch deck tracking for genomics startups.
Best genomics investors
1. ARCH Venture Partners
Pioneer in genomics investing with deep scientific expertise.
Investment focus: Platform technologies, genetic medicines, sequencing innovation
Investment range: Series A to growth, $10M-$100M+
Notable investments: Illumina (early), Grail, Adaptive Biotechnologies
Contact: archventure.com
2. OrbiMed
Healthcare specialist with dedicated genomics practice.
Investment focus: Genetic testing, precision medicine, genomic therapeutics
Investment range: Series B+, $20M-$200M
Notable investments: Complete Genomics, Foundation Medicine, Invitae
Contact: orbimed.com
3. ARK Invest
Public market investor with genomic revolution strategy.
Investment focus: DNA sequencing, CRISPR, gene therapy, molecular diagnostics
Investment range: Public markets, also private rounds
Notable investments: Genomic Revolution ETF (ARKG)
Contact: ark-invest.com
4. Flagship Pioneering
Company creation platform specializing in genomics.
Investment focus: Novel genomic platforms, computational genomics
Investment range: Seed to growth through company creation
Notable investments: Moderna, Generate Biomedicines, Tessera Therapeutics
Contact: flagshippioneering.com
5. Illumina Ventures
Corporate venture arm of sequencing leader.
Investment focus: Genomics applications, sequencing tech, clinical genomics
Investment range: Series A-B, $5M-$20M
Notable investments: Helix, Genome Medical, Element Biosciences
Contact: illuminaventures.com
6. GE Healthcare Ventures
Strategic investor in genomic diagnostics.
Investment focus: Clinical genomics, diagnostic platforms
Investment range: Series A-C, strategic investments
Notable investments: Genome Medical, genomic diagnostic companies
Contact: gehealthcare.com/ventures
7. Casdin Capital
Life sciences specialist focused on genomics.
Investment focus: Genomic medicine, precision oncology, genetic tools
Investment range: Growth equity, $25M-$100M+
Notable investments: Exact Sciences, 10x Genomics, Adaptive
Contact: casdincapital.com
8. Section 32
Bill Maris's fund with genomics focus.
Investment focus: Computational genomics, genetic engineering
Investment range: Seed to growth
Notable investments: Verily, genomic platform companies
Contact: section32.com
9. Foresite Capital
Multi-stage healthcare investor in genomics.
Investment focus: Precision medicine, genomic therapeutics
Investment range: Series A to growth, $10M-$100M
Notable investments: 10x Genomics, Twist Bioscience
Contact: foresitecapital.com
10. Highland Capital Partners
Early-stage investor backing genomics pioneers.
Investment focus: Genomics platforms, genetic testing
Investment range: Series A-B, $5M-$25M
Notable investments: Complete Genomics, genomic startups
Contact: hcp.com
11. Third Rock Ventures
Company builder in genomics and genetic medicine.
Investment focus: Transformative genetic medicines, platform technologies
Investment range: Company creation to growth
Notable investments: Foundation Medicine, Editas Medicine, Magenta Therapeutics
Contact: thirdrockventures.com
12. Sands Capital
Growth investor in genomic leaders.
Investment focus: Market-leading genomics companies
Investment range: Growth equity, $50M+
Notable investments: Complete Genomics, public genomics companies
Contact: sandscapital.com
13. Kaiser Permanente Ventures
Healthcare system investing in genomics.
Investment focus: Clinical genomics, population health genomics
Investment range: Series A-C, $5M-$20M
Notable investments: Genome Medical, clinical genomics companies
Contact: kp-ventures.com
14. Johnson & Johnson Innovation
Corporate venture in genetic medicine.
Investment focus: Genetic therapeutics, precision diagnostics
Investment range: Strategic investments across stages
Notable investments: Gene therapy and genetic medicine companies
Contact: jnjinnovation.com
15. Roche Venture Fund
Pharma giant's genomics investment arm.
Investment focus: Molecular diagnostics, personalized healthcare
Investment range: Series A-C, strategic investments
Notable investments: Foundation Medicine (acquired), genomic diagnostics
Contact: roche.com/ventures
16. Y Combinator
Leading accelerator with genomics track record.
Investment focus: Early-stage genomics startups
Investment range: $500K for 7%
Notable investments: Numerous genomics companies
Contact: ycombinator.com
17. Seven Seven Six
Alexis Ohanian's fund investing in genomics.
Investment focus: Consumer genomics, genetic testing innovation
Investment range: Seed to Series A
Notable investments: Nucleus Genomics
Contact: sevensevensix.com
18. Bain Capital Life Sciences
Growth equity in genomics leaders.
Investment focus: Commercial-stage genomics companies
Investment range: $50M-$200M+
Notable investments: Genomics diagnostic companies
Contact: baincapitallifesciences.com
19. FirstMark Capital
NYC-based investor in genomics innovation.
Investment focus: Genomics platforms, genetic health
Investment range: Seed to Series B
Notable investments: Genomics startups
Contact: firstmarkcap.com
20. Alexandria Venture Investments
Real estate giant's life science venture arm.
Investment focus: Genomics infrastructure, platform companies
Investment range: Series A-C
Notable investments: Genomics companies in Alexandria properties
Contact: alexandriainvest.com
21. Fidelity Biosciences
Crossover investor in genomics.
Investment focus: Late-stage genomics companies
Investment range: Series C+, $25M-$100M
Notable investments: Public and private genomics leaders
Contact: fidelitybiosciences.com
22. Perceptive Advisors
Healthcare hedge fund investing in genomics.
Investment focus: Public and private genomics companies
Investment range: Growth to public markets
Notable investments: Major genomics companies
Contact: perceptivelife.com
23. RA Capital Management
Crossover fund with genomics expertise.
Investment focus: Genetic medicines, platform technologies
Investment range: Series B to public
Notable investments: Gene therapy and editing companies
Contact: racap.com
24. Sofinnova Partners
European life sciences investor.
Investment focus: European genomics companies
Investment range: Series A-C, €10M-€50M
Notable investments: European genomics leaders
Contact: sofinnovapartners.com
25. Deerfield Management
Healthcare investment firm in genomics.
Investment focus: Genomic medicine, diagnostics
Investment range: All stages, $10M-$200M+
Notable investments: Genomics therapeutics and diagnostics
Contact: deerfield.com
26. Polaris Partners
Early-stage genomics investor.
Investment focus: Genomics platforms, precision medicine
Investment range: Series A-B
Notable investments: Genomics startups
Contact: polarispartners.com
27. MPM Capital
Life sciences specialist in genomics.
Investment focus: Genetic medicines, genomic tools
Investment range: Series A to growth
Notable investments: Genomics therapeutic companies
Contact: mpmcapital.com
28. Versant Ventures
Healthcare VC with genomics focus.
Investment focus: Gene therapy, genetic tools
Investment range: Series A-C
Notable investments: Genomics platform companies
Contact: versantventures.com
29. Viking Global Investors
Crossover investor in genomics leaders.
Investment focus: Late-stage genomics companies
Investment range: $50M+ rounds
Notable investments: Major genomics companies
Contact: vikingglobal.com
30. Matrix Partners
Early-stage investor in genomics innovation.
Investment focus: Genomics software, computational biology
Investment range: Seed to Series B
Notable investments: Genomics tech companies
Contact: matrixpartners.com
31. Khosla Ventures
Tech investor embracing genomics.
Investment focus: Breakthrough genomics technologies
Investment range: Seed to growth
Notable investments: Next-gen sequencing companies
Contact: khoslaventures.com
32. GV (Google Ventures)
Alphabet's venture arm in genomics.
Investment focus: Computational genomics, AI-driven genomics
Investment range: Series A-C
Notable investments: Genomics AI companies
Contact: gv.com
How to approach genomics investors
What genomics VCs actually evaluate
Technical moat matters most. Show your sequencing accuracy, cost per genome, or unique biological insights.
Key metrics:
- Cost per genome/test
- Turnaround time
- Clinical validity data
- Regulatory status (CLIA, FDA)
Differentiation requirements
Me-too genetic tests don't get funded. You need:
- Proprietary technology or algorithms
- Exclusive data partnerships
- Novel clinical applications
- Clear path to reimbursement
Due diligence preparation
Genomics investors go deep. Expect:
- Technical architecture reviews
- Bioinformatics pipeline audits
- Clinical validation studies
- Regulatory pathway discussions
Have your data room ready with validation studies, patents, and regulatory correspondence.
Alternative genomics funding sources
Government grants
NIH/NHGRI: Up to $5M for genomics research
SBIR/STTR: $2M for genomics commercialization
EU Horizon: €2.5M for European genomics companies
ARPA-H: New funding for breakthrough genomics
Strategic partnerships
Illumina Accelerator: Sequencing credits + $100K
Thermo Fisher: Strategic investments in genomics tools
10x Genomics: Compatible technology partnerships
Quest/LabCorp: Clinical channel partnerships
Disease foundations
Many foundations fund genomics research:
- Cystic Fibrosis Foundation
- JDRF (Type 1 diabetes)
- Michael J. Fox Foundation
- ALS Association
Success stories
Platform winners
Illumina: Dominated short-read sequencing. $45B peak market cap.
10x Genomics: Single-cell sequencing leader. $10B valuation achieved.
Foundation Medicine: Sold to Roche for $5.3B. Validated genomic oncology.
Emerging successes
Element Biosciences: Raised $277M challenging Illumina.
Ultima Genomics: $600M raised for $100 genome.
Singular Genomics: IPO'd despite Illumina competition.
Why genomics startups fail
Technology wasn't 10x better. Marginal improvements don't win.
Ignored reimbursement. Great tech without payment model.
Competed on price alone. Race to bottom in commoditized testing.
How Ellty helps genomics startups
Genomics pitch decks require technical depth. Investors scrutinize sequencing metrics, validation data, and regulatory pathways.
Ellty shows you:
- Which technical slides get studied longest
- When investors forward to scientific advisors
- Who downloads your validation data
Genomics founders report:
- 3.5x higher response rates with tracking
- Know which VCs have genomics expertise
- Identify who shares with clinical teams
FAQs
Q: How much for genomics seed round?
$3-10M typical. Higher than software due to lab costs.
Q: Do we need CLIA certification first?
Not for seed, but clear path required by Series A.
Q: Should we publish our methods?
Only if IP is protected. Trade secrets often better.
Q: B2B or B2C genomics?
B2B easier path. Consumer genomics faces regulatory scrutiny.
Q: How long to first revenue?
2-3 years typical for clinical validation and launch.
